Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 4,670 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Respiratory Therapy Clear all

Conditions: Survivorship
Interventions: LiveWell: An Adapted Dialectical Behavioral Therapy Skills Training Program; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Covid19
Interventions: Placebo injection and placebo pill, Estradiol Cypionate 5 mg/ml, Progesterone 200 mg Oral Capsule; Other · Drug
Lead sponsor: Tulane University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma, NSCLC, NSCLC Stage IV
Interventions: L-SABR, Anti-PD-(L)1 based immunotherapy, Platinum based chemotherapy; Radiation · Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 9
States / cities: Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more

Conditions: NSCLC
Interventions: Aliya Pulsed Electric Fields (PEF) ablation, Nivolumab plus Platinum Doublet Chemotherapy, Standard of care neoadjuvant therapy, Surgical Resection; Device · Drug · Other
Lead sponsor: Galvanize Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Rochester, Minnesota • Philadelphia, Pennsylvania

Conditions: Cystic Fibrosis, Pulmonary Disease, Chronic Obstructive
Interventions: Tobramycin solution for inhalation (TOBI), Oral placebo, Oral ciprofloxacin; Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 1 Year to 12 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 54
States / cities: Birmingham, Alabama • Los Angeles, California • Oakland, California + 49 more

Conditions: Alpha 1-Antitrypsin Deficiency
Interventions: AAV8hAAT(AVL); Biological
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma Chronic
Interventions: Azithromycin, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 55 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Acute Respiratory Failure
Interventions: intensive physical therapy, control group; Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 5
States / cities: Aurora, Colorado • Denver, Colorado • Englewood, Colorado + 1 more

Conditions: Covid19, Cytokine Storm, Inflammation
Interventions: Splenic Ultrasound; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Burnsville, Minnesota • Saint Paul, Minnesota

Conditions: Advanced Malignancies, Metastatic Cancer
Interventions: INCAGN01876, Epacadostat, Pembrolizumab; Drug
Lead sponsor: Incyte Biosciences International Sàrl; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Los Angeles, California • Hackensack, New Jersey

Conditions: Brain Cancer, Prostate Cancer, Lung Cancer
Interventions: Not listed
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Cytokine Release Syndrome, COVID19
Interventions: Therapeutic Plasma Exchange, Ruxolitinib; Procedure · Drug
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 12 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Presbyphonia
Interventions: PhoRTE Program, University of California Los Angeles (UCLA) Loneliness Scale, Social Disconnectedness Scale, Patient Health Questionnaire 9, Aging Voice Index, The Edmonton Frail Scale, Vocal Effort Scale, Montreal Cognitive Assessment, Voice Handicap Index-10, Voice Problem Impact Scales, Cough Severity Index, Laryngoscopy, Acoustic, perceptual, and aerodynamic assessments; Other · Procedure
Lead sponsor: Matthew R. Hoffman; Other
Eligibility: 65 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Sleep Disordered Breathing, Able Bodied
Interventions: Acetazolamide + supplemental oxygen + PAP therapy, Zolpidem + PAP therapy, Buspirone + PAP therapy; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Metastatic Non-small Cell Lung Cancer
Interventions: Dato-DXd, Osimertinib, Pemetrexed, Carboplatin, Cisplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 768 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 9
States / cities: Fayetteville, Arkansas • Fountain Valley, California • San Diego, California + 6 more

Conditions: Olfactory Disorder, Olfaction Disorders, Olfactory Nerve Injuries, Olfactory Nerve Disorder, Olfactory Nerve Diseases, Covid19, Post-Viral Disorder
Interventions: Injection into olfactory cleft; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: San Diego, California • Stanford, California

Conditions: Cognitive/Functional Effects, Delirium, Depression, Lung Cancer, Radiation Toxicity
Interventions: vitamin E, donepezil hydrochloride, placebo; Dietary Supplement · Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 15
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 12 more

Conditions: SARS-CoV 2
Interventions: Phase 1, Phase 2; Radiation
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 40 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-Small-Cell Lung Carcinoma
Interventions: Pemetrexed, Cisplatin, Cixutumumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 5
States / cities: Chicago, Illinois • Hackensack, New Jersey • Portland, Oregon + 2 more

Conditions: Cystic Fibrosis
Interventions: VX-445/TEZ/IVA, IVA, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 53
States / cities: Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 48 more

Conditions: COPD Exacerbation
Interventions: Formoterol, Placebo; Drug · Other
Lead sponsor: University of Tennessee Graduate School of Medicine; Other
Eligibility: 40 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Non-Small Cell Lung Cancer
Interventions: Ipilimumab, Nivolumab, Carboplatin, Paclitaxel, Pemetrexed, Cisplatin; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 719 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 16
States / cities: Colorado Springs, Colorado • Plainville, Connecticut • Jacksonville, Florida + 12 more

Conditions: Pneumonia, Bacterial
Interventions: ME1100 inhalation solution; Drug
Lead sponsor: Meiji Seika Pharma Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 14
States / cities: Martinez, California • Sacramento, California • San Diego, California + 11 more

Conditions: Lung Cancer
Interventions: carboplatin, Erlotinib, paclitaxel, conventional surgery, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Nathan Pennell, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

LiveWell: An Adapted Dialectical Behavioral Therapy Skills Training Protocol for Patients Living With Metastatic Lung Cancer

Estradiol and Progesterone in Hospitalized COVID-19 Patients

A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)

Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC

Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis

Gene Therapy for Alpha 1- Antitrypsin Deficiency

Azithromycin Treatment for the Airway Microbiome in Asthma

Treatment of Critical Illness Polyneuromyopathy

UNITE Study (UMN-SW) for COVID-19

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Feasibility Study of Tumor Blood Flow Measurement by Detection of Positron Activation Post Proton Therapy (DS01)

Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS

Characterizing the Impact of Presbyphonia on Social Interaction

Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Intranasal Injection of PRP Versus Saline for Treatment of Olfactory Dysfunction

Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer

Lung Irradiation for COVID-19 Pneumonia

A Study in Non-Small Cell Lung Cancer

A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers

A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC

A Study to Assess the Pharmacokinetic Profile, the Safety, and the Tolerability of ME1100 Inhalation Solution in Patients With Mechanically Ventilated Bacterial Pneumonia

Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer